The board of directors of Allergan plc (NYSE:AGN) approved a dividend of USD0.72 per ordinary share for the Q4 2018, the company declared on Friday.

This cash dividend is due on 14 December 2018 to shareholders of record at the close of business as of 13 November 2018.

Headquartered in Dublin, Ireland, the pharmaceutical company is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

In addition, the company markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.